cometadata/datacite-titles-descriptions-related-identifiers huggingface dataset:
DOI: 10.15468/dl.jutz59
title: Occurrence Download

description: A dataset containing 1019 species occurrences available in GBIF matching the query:
{
 "and" : [
 "TaxonKey is Manniophyton fulvum",
 "HasCoordinate is true",
 "BasisOfRecord is one of (Specimen)"
 ]
}

 The dataset includes 1019 records from 30 constituent datasets; see https://api.gbif.org/v1/occurrence/download/0003263-260129131611470/datasets/export for details.
 
Data from some individual datasets included in this download may be licensed under less restrictive terms.
DOI: 10.15468/dl.wvqgsb
title: Occurrence Download

description: A dataset containing 4593 species occurrences available in GBIF matching the query:
{
 "and" : [
 "OccurrenceStatus is Present",
 "TaxonKey is Sterculia tragacantha"
 ]
}

 The dataset includes 4593 records from 161 constituent datasets; see https://api.gbif.org/v1/occurrence/download/0025416-250811113504898/datasets/export for details.
 
Data from some individual datasets included in this download may be licensed under less restrictive terms.
DOI: 10.15468/dl.fer7w4
title: Occurrence Download

description: A dataset containing 241 species occurrences available in GBIF matching the query:
{
 "and" : [
 "Country is one of (China, Chinese Taipei, Hong Kong, Macao)",
 "HasCoordinate is true",
 "HasGeospatialIssue is false",
 "TaxonKey is Rhamnus davurica P.Lawson"
 ]
}

 The dataset includes 241 records from 6 constituent datasets; see https://api.gbif.org/v1/occurrence/download/0001744-250424135625364/datasets/export for details.
 
Data from some individual datasets included in this download may be licensed under less restrictive terms.
DOI: 10.15468/dl.dpak3x
title: Occurrence Download

description: A dataset containing 29 species occurrences available in GBIF matching the query:
{
 "and" : [
 "GadmGid is BRA.8_1",
 "HasCoordinate is true",
 "HasGeospatialIssue is false",
 "OccurrenceStatus is Present",
 "TaxonKey is Triatoma vitticeps (Stål, 1859)"
 ]
}

 The dataset includes 29 records from 3 constituent datasets; see https://api.gbif.org/v1/occurrence/download/0001745-250424135625364/datasets/export for details.
 
Data from some individual datasets included in this download may be licensed under less restrictive terms.
DOI: 10.5281/zenodo.12729031
title: Data From: PD-linked LRRK2 G2019S mutation impairs astrocyte morphology and synapse maintenance via ERM hyperphosphorylation

description: Source data files for Wang et al 'PD-linked LRRK2 G2019S mutation impairs astrocyte morphology and synapse maintenance via ERM hyperphosphorylation'
DOI: 10.5281/zenodo.12729032
title: Data From: Astrocytic LRRK2 Controls Synaptic Connectivity via Regulation of ERM phosphorylation

description: Tabular raw data corresponding to figure sets used in the study. 

Figure 1: ERM phosphorylation is impaired in PD patients carrying LRRK2 G2019S mutation.

Figure S1 (Related to Figure 1): Phospho-ERM is upregulated in LRRK2 G2019Ski/ki astrocytes in ACC and MOp but not SSp and DMS.

Figure S2 (Related to Figure 1): GFAP level is not altered in LRRK2 G2019Ski/ki astrocytes in ACC and MOp.

Figure 2: LRRK2 G2019S affects excitatory and inhibitory synapse numbers in the ACC and MOp. 

Figure S3 (Related to Figure 2): LRRK2 G2019S does not change excitatory synapse numbers in the primary motor cortex.

Figure 3: LRRK2 G2019S affects excitatory and inhibitory synapse function in the ACC and MOp.

Figure 4: Overexpression of phospho-dead Ezrin in adult LRRK2 G2019Ski/ki astrocytes restores excitatory synapse number and function in the ventral ACC.

Figure S4 (Related to Figure 4): Overexpression of AAV-HA-tagged-WT Ezrin and AAV-HA-tagged-Phospho-dead Ezrin in WT and LRRK2 G2019Ski/ki astrocytes.

Figure S5 (Related to Figure 4): Overexpression of AAV-HA-tagged-WT Ezrin and AAV-HA-tagged-Phospho-dead Ezrin in WT and LRRK2 G2019Ski/ki astrocytes.

Figure 5: Astrocytic LRRK2 controls astrocyte morphology by balancing ERM phosphorylation levels in vivo. 

Figure S6 (Related to Figure 5): LRRK2 G2019S does not change ALDH1L1+/SOX9+ cell numbers in the ACC and MOp. 

Figure S7 (Related to Figure 5): Localization and expression of LRRK2 in astrocytes.

Figure 6: LRRK2 G2019S alters the interactome of astrocytic Ezrin in vivo.

Figure S9: LRRK2 G2019S changes the composition of cytoplasmic proteins in astrocytes in vivo. 

Figure 7: Interaction Between Atg7 and Ezrin Depends on Ezrin's Phosphorylation State.

Figure S10: Astrocytic Atg7 is essential astrocyte morphological complexity in vitro.
DOI: 10.5281/zenodo.14781771
title: Data From: Astrocytic LRRK2 Controls Synaptic Connectivity via Regulation of ERM phosphorylation

description: Tabular raw data corresponding to figure sets used in the study. 



Phospho-ERM Antibody Validation: We confirmed the specificity of the phospho-ERM antibody by treating brain sections from both mice and human samples with lambda protein phosphatase (λ-PPase), which dephosphorylates proteins. In both cases, the phospho-ERM signal was eliminated after λ-PPase treatment, confirming the specificity of phospho-ERM antibodies in mouse and human samples.

Cell-type specificity of pERM staining in mouse and human brains: We assessed ERM hyperphosphorylation for cell-type-specific by co-staining phospho-ERM with cellular markers. In LRRK2 G2019Ski/ki mice, phospho-ERM was significantly increased in ACC and MOp L1 and L2/3, colocalizing with S100β (astrocytes) and MAP2 (neurons) but not Iba1 (microglia), with predominant astrocytic localization. PD patients with the LRRK2 G2019S mutation showed elevated phospho-ERM colocalized with S100β and MAP2 in the frontal cortices.
DOI: 10.5281/zenodo.14812081
title: Data From: Astrocytic LRRK2 Controls Synaptic Connectivity via Regulation of ERM phosphorylation

description: Updated Supplemental Information

Figure S1: Phospho-ERM is upregulated in LRRK2 G2019Ski/ki astrocytes in ACC and MOp but not SSp and DMS. Related to Figure 1.

Figure S2: phospho-ERM is eliminated after Lambda protein phosphatase (λ-PPase) treatment. Related to Figure 1.

Figure S3: phospho-ERM is significantly increased and colocalizes with S100β and MAP2. Related to Figure 1.

Figure S4: ERM and GFAP levels are not altered in LRRK2 G2019Ski/ki ACC and MOp. Related to Figure 1.

Figure S5: LRRK2 G2019S does not change excitatory synapse numbers in the primary motor cortex. Related to Figure 2.

Figure S6: Overexpression of AAV-HA-tagged-WT Ezrin and AAV-HA-tagged-Phospho-dead Ezrin in WT and LRRK2 G2019Ski/ki astrocytes. Related to Figure 4.

Figure S7: Overexpression of AAV-HA-tagged-WT Ezrin and AAV-HA-tagged-Phospho-dead Ezrin in WT and LRRK2 G2019Ski/ki astrocytes. Related to Figure 4.

Figure S8: WT Ezrin overexpression does not change excitatory synapse numbers in the ACC of WT mice. Related to Figure 4.

Figure S9: Overexpression of AAV-HA-tagged-WT Ezrin and AAV-HA-tagged-Phospho-dead Ezrin in WT and LRRK2 G2019Ski/ki astrocytes. Related to Figure 4.

Figure S10: LRRK2 G2019S does not change ALDH1L1+/SOX9+ cell numbers in the ACC and MOp. Related to Figure 5. 

Figure S11: Localization and expression of LRRK2 in astrocytes. Related to Figure 5. 

Figure S12: BioID constructs expression and biotinylation in vivo and in vitro. Related to Figure 6.

Figure S13: LRRK2 G2019S changes the composition of cytoplasmic proteins in astrocytes in vivo. Related to Figure 6. 

Figure S14: Astrocytic Atg7 is essential astrocyte morphological complexity in vitro. Related to Figure 7.
DOI: 10.5281/zenodo.14990945
title: Data From: PD-linked LRRK2 G2019S mutation impairs astrocyte morphology and synapse maintenance via ERM hyperphosphorylation

description: Reorganized source data files
DOI: 10.5281/zenodo.15282825
title: Data From: PD-linked LRRK2 G2019S mutation impairs astrocyte morphology and synapse maintenance via ERM hyperphosphorylation

description: Source data files for Wang et al 'PD-linked LRRK2 G2019S mutation impairs astrocyte morphology and synapse maintenance via ERM hyperphosphorylation'
DOI: 10.15468/dl.93w4q2
title: Occurrence Download

description: A dataset containing 68536 species occurrences available in GBIF matching the query:
{
 "TaxonKey" : [
 "is Liriodendron tulipifera"
 ]
}

 The dataset includes 68536 records from 626 constituent datasets; see https://api.gbif.org/v1/occurrence/download/0025614-250811113504898/datasets/export for details.
 
Data from some individual datasets included in this download may be licensed under less restrictive terms.
DOI: 10.25934/pr00009379
title: A PHASE 3 RANDOMIZED, DOUBLE-BLIND, DOUBLE-DUMMY, PLACEBO-CONTROLLED, PARALLEL GROUP, MULTI-CENTER STUDY INVESTIGATING THE EFFICACY AND SAFETY OF PF-04965842 AND DUPILUMAB IN COMPARISON WITH PLACEBO IN ADULT SUBJECTS ON BACKGROUND TOPICAL THERAPY, WITH MODERATE TO SEVERE ATOPIC DERMATITIS

description: B7451029 is a Phase 3 study to investigate PF-04965842 in adult patients who have moderate to severe atopic dermatitis and use background topical therapy. The efficacy of two dosage strengths of PF-04965842, 100 mg and 200 mg taken orally once daily will be evaluated relative to placebo over 12 weeks. The efficacy of the two dosage strengths of PF-04965842 will be compared with dupilumab in terms of pruritus relief at 2 weeks. The two dosage strengths of PF-04965842 and dupilumab 300 mg injected subcutaneously once every two weeks (with a loading dose of 600 mg injected on the first day) will also be evaluated relative to placebo over 16 weeks. The safety of the investigational products will be evaluated over the duration of the study. Subjects will use non-medicated emollient at least twice a day and medicated topical therapy such as corticosteroids, calcineurin inhibitors or PDE4 inhibitors, as per protocol guidance, to treat active lesions during the study. Subjects who are randomized to receive one of the two dosage strengths of PF-04965842 will also receive placebo injectable study drug every two weeks until Week 16 and then will continue on receiving only the oral study drug for 4 weeks. Subjects who are randomized to receive dupilumab injections every two weeks will also receive oral placebo to be taken once daily until Week 16 and will then continue to receive only the oral placebo for 4 weeks. Subjects who are randomized to the placebo arms, will receive both daily oral placebo and injectable placebo every two weeks until Week 16, after which they will receive either 100 mg or 200 mg of PF-04965842 taken orally once daily for 4 weeks, dependent upon which arm they have been allocated to. Eligible subjects will have an option to enter a long-term extension study after completing 20 weeks of treatment.
DOI: 10.25934/00000214
title: Immunogenicity: 3 Consecutive Lots of GSK Biologicals' HPV-16/18 Vaccine Administered Intramuscularly at 0,1,6 Month Schedule in Healthy Females Aged 10-25 Years and Demonstrate Non-inferiority of Candidate HPV Vaccine Manufactured by Modified Production Process

description: Human Papilloma virus (HPV) are viruses that cause a common infection of the skin and genitals in men and women. Several types of HPV infection are transmitted by sexual activity and, in women, can infect the cervix (part of the uterus or womb). This infection often goes away by itself, but if it does not go away (this is called persistent infection), it can lead in women over a long period of time to cancer of the cervix. If a woman is not infected by HPV, it is very unlikely that she will get cervical cancer. This study will evaluate the consistency of consecutive vaccine lots and the non-inferiority of modified manufacturing processes of GSK Biologicals HPV-16/18 vaccine and the vaccine safety, over 12 months, in young adolescents and women of 10-25 years of age at study start. Approximately 750 study subjects will receive different lots of the HPV vaccine administered intramuscularly according to a 0-1-6 month schedule.
DOI: 10.25934/00000506
title: GSK1572932A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Resectable MAGE-A3 Positive Non-Small Cell Lung Cancer

description: The purpose of this clinical trial is to demonstrate the benefit of the immunotherapeutic product GSK1572932A when given to patients with Non-Small Cell Lung Cancer, after removal of their tumor. A course of 13 injections will be administered over 27 months. The Protocol Posting has been updated in order to comply with the FDA Amendment Act, Sep 2007.
DOI: 10.25934/00001386
title: A Randomized Phase III Trial of Three Different Regimens of CPT-11 Plus 5-Fluorouracil and Leucovorin Compared to 5-Fluorouracil and Leucovorin in Patients With Advanced Adenocarcinoma of the Colon and Rectum

description: RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. It is not yet known which regimen of combination chemotherapy is most effective in treating advanced colorectal cancer. PURPOSE: Randomized phase III trial to compare the effectiveness of various combination chemotherapy regimens in treating patients who have advanced, recurrent, or metastatic colorectal cancer that cannot be treated with surgery or radiation therapy.
DOI: 10.25934/00003587
title: A Phase IIb, Randomized, Double-blind, Placebo-controlled, Parallel Group, Safety and Efficacy Study of BI 10773 (10 mg and 25 mg) Administered Orally, Once Daily Over 78 Weeks in Type 2 Diabetic Patients Receiving Treatment With Basal Insulin (Glargine, Detemir, or NPH Insulin Only) With or Without Concomitant Metformin and/or Sulfonylurea Therapy and Insufficient Glycemic Control

description: The objective of the current study is to investigate the efficacy, safety and tolerability of BI 10773 at two different doses compared to placebo during long term treatment (78 weeks) in combination with basal insulin in patients with type 2 diabetes mellitus with insufficient glycaemic control.
DOI: 10.25934/00004457
title: A Phase III Open-label Extension of the MTE08 Trial (A Phase III Open-label Titration Trial to Evaluate the Effectiveness and Safety of Different Doses of a Dermal Application of Testosterone MD-Lotion® (Cutaneous Solution) in Hypogonadal Men) to Evaluate Skin-safety

description: Testosterone replacement treatment is the most effective way of treating hypogonadism in men. Acrux has a propriety testosterone replacement product, Testosterone MD-Lotion and this study will assess the occurrence of skin safety events for a further two months of continuous use of the Testosterone MD-Lotion® (cutaneous solution) after completion of the MTE08 (NCT00702650) trial.
DOI: 10.25934/00005155
title: A Phase III, Randomized, Double Blind, Placebo-controlled Clinical Study to Assess the Efficacy and Safety of GSK2402968 in Subjects With Duchenne Muscular Dystrophy

description: The purpose of this study is to determine whether GSK2402968 is effective in the treatment of ambulant boys with Duchenne muscular dystrophy resulting from a mutation thought to be corrected by exon 51 skipping.
DOI: 10.25934/00005679
title: A Randomized, Three Arm Multinational Phase III Study to Investigate Bevacizumab (q3w or q2w) in Combination With Either Intermittent Capecitabine Plus Oxaliplatin (XELOX) (q3w) or Fluorouracil/Leucovorin With Oxaliplatin (FOLFOX-4) Versus FOLFOX-4 Regimen Alone as Adjuvant Chemotherapy in Colon Carcinoma: The AVANT Study

description: RATIONALE: Drugs used in chemotherapy work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Bevacizumab (Bv) may also stop the growth of tumor cells by blocking blood flow to the tumor. Giving combination chemotherapy together with bevacizumab after surgery may kill any tumor cells that remain after surgery. It is not yet known whether giving combination chemotherapy together with bevacizumab is more effective than combination chemotherapy alone in treating colon cancer in adjuvant setting. PURPOSE: This randomized phase III trial is studying two different combination chemotherapy regimens with or without bevacizumab to compare how well they work in treating patients who have undergone surgery for high risk stage II or stage III colon cancer.
DOI: 10.25934/00006230
title: A Phase I, Open-Label, Non-Randomised, Multicentre Study to Assess the Effect of AZD9291 on the Pharmacokinetics of Rosuvastatin (a Sensitive BCRP Substrate) in Patients With EGFRm Positive NSCLC Whose Disease Has Progressed on an EGFR TKI

description: This is a Phase I, open-label, 2-part study in patients with a confirmed diagnosis of epidermal growth factor receptor (EGFR) mutation positive (EGFRm+) non-small cell lung cancer (NSCLC), who have progressed following prior therapy with an approved EGFR tyrosine kinase inhibitor (TKI) agent. Part A will assess the effect of AZD9291 on the pharmacokinetic (PK) parameters of rosuvastatin, following multiple oral dosing of AZD9291 in the fasted state. Part B will allow patients further access to AZD9291 after the PK phase (Part A) and will provide for additional safety data collection. All patients from Part A who completed treatment may continue to receive AZD9291 80 mg once daily as a single agent until: disease progression; they are no longer deriving clinical benefit; or any other reason.
DOI: 10.25934/00001425
title: CHAARTED: ChemoHormonal Therapy Versus Androgen Ablation Randomized Trial for Extensive Disease in Prostate Cancer

description: RATIONALE: Androgens can cause the growth of prostate cancer cells. Androgen ablation therapy may stop the adrenal glands from making androgens. Drugs used in chemotherapy, such as docetaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. It is not yet known whether androgen-ablation therapy is more effective with or without docetaxel in treating metastatic prostate cancer. PURPOSE: This randomized phase III trial is studying androgen-ablation therapy and chemotherapy to see how well they work compared to androgen-ablation therapy alone in treating patients with metastatic prostate cancer.
DOI: 10.25934/00002521
title: A Phase 1, Randomized, Open-Label, Parallel Design, Multicenter Study to Evaluate the Pharmacokinetics and Safety of Dexlansoprazole Delayed Release Capsules in Pediatric Subjects Ages 1 to 11 Years Old With Symptomatic Gastroesophageal Reflux Disease

description: The purpose of this study is to assess the pharmacokinetics and safety of dexlansoprazole, once daily (QD), in pediatric subjects with symptomatic Gastroesophageal Reflux Disease.
DOI: 10.25934/00002861
title: A Double-Blind, Multicenter, Extension Study to Evaluate the Safety and Efficacy of DAC HYP in Subjects With Multiple Sclerosis Who Have Completed Treatment in Study 205MS201 (SELECT)

description: The primary objective of the study was to assess the safety and immunogenicity of extended treatment with DAC HYP. This evaluation included the following major components:   -  An assessment of safety and immunogenicity of extended treatment with DAC HYP when administered to MS subjects who had completed 52 weeks of active therapy with DAC HYP in Study 201.   -  An assessment of safety and immunogenicity during a 6-month washout period from DAC HYP.   -  An assessment of safety and immunogenicity during reinitiation of therapy with DAC HYP after a 6-month washout period.   -  An assessment of safety and immunogenicity of DAC HYP when administered to MS subjects who previously received placebo during Study 201. The secondary objective is to assess the durability of the effect of DAC HYP on multiple sclerosis (MS) disease activity as measured by brain magnetic resonance imaging (MRI) scans and clinical MS relapses.
DOI: 10.25934/00003242
title: Non-inferiority Study of GSK Biologicals' Pandemic Influenza Vaccine 1562902A.

description: This observer-blind study is designed to show the immunological non-inferiority of Thiomersal-free-processed pandemic influenza vaccine as compared to the Thiomersal-containing-processed pandemic influenza vaccine.
DOI: 10.25934/00004181
title: Duloxetine Once-Daily Dosing
Versus Placebo in the Acute Treatment of Major Depression

description: Vivli is an independent, non-profit organization that has developed a global data-sharing and analytics platform to serve all elements of the international research community. Our mission is to promote, coordinate, and facilitate scientific sharing and reuse of clinical research data through the creation and implementation of a sustainable global data-sharing enterprise. The Vivli platform includes an independent data repository, in-depth search engine and a cloud-based, secure analytics platform.
DOI: 10.25934/00004511
title: A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib (LY3009104) in Patients With Inadequate Response to Conventional Disease-Modifying Antirheumatic Drugs With Moderately to Severely Active Rheumatoid Arthritis

description: The purpose of this study is to determine whether baricitinib 4 milligram (mg) once daily (QD) is superior to placebo in the treatment of participants with moderately to severely active Rheumatoid Arthritis (RA) who have had inadequate response to or are intolerant to at least 1 conventional disease-modifying antirheumatic drug (cDMARD)(cDMARD-IR [inadequate response] participants) and who have not received a biologic disease-modifying antirheumatic drug (DMARD).
DOI: 10.25934/00007249
title: A Multicenter, Randomized, Double-Blind, Parallel-Group Study of Gene-Activated® Human Glucocerebrosidase (GA-GCB) Enzyme Replacement Therapy Compared With Imiglucerase in Patients With Type I Gaucher Disease

description: Gaucher disease is a rare lysosomal storage disorder caused by the deficiency of the enzyme glucocerebrosidase (GCB). Due to the deficiency of functional GCB, glucocerebroside accumulates within macrophages leading to cellular engorgement, organomegaly, and organ system dysfunction. The purpose of this non-inferiority study is to evaluate the efficacy and safety of GA-GCB (velaglucerase alfa) administered every other week in comparison to imiglucerase in treatment naive patients with type 1 Gaucher disease.
DOI: 10.25934/pr00008597
title: A Phase III, Randomised, Double Blind, Placebo-controlled, Parallel Group, Efficacy, Safety and Tolerability Trial of Once Daily, Oral Doses of Empagliflozin as Adjunctive to inSulin thErapy Over 52 Weeks in Patients With Type 1 Diabetes Mellitus (EASE-2)

description: Comparison of 2 doses of empagliflozin vs placebo in patients already using either an insulin regimen of multiple daily injections (MDI) or continuous subcutaneous insulin infusion (CSII). Randomisation to 3 treatments arms (equal assignment) following a screening period, an optimisation period and a run-in period. 52 week double-blind treatment period, and 3 week follow-up period.
DOI: 10.25934/pr00010738
title: A Phase 3, Multicenter, Randomized, Double Blind, Placebo-Controlled Study to Confirm the Safety, Tolerability, and Efficacy of Zilucoplan in Subjects With Generalized Myasthenia Gravis

description: The RAISE study is a multicenter, randomized, double-blind, placebo controlled study to confirm the efficacy, safety, and tolerability of zilucoplan in subjects with generalized Myasthenia Gravis. Subjects will be randomized in a 1:1 ratio to receive daily SC doses of 0.3 mg/kg zilucoplan or placebo for 12 weeks.
DOI: 10.25934/00000671
title: A Randomised, Double-blind, Placebo-controlled Study to Assess the Effect of Oral, Single Dose SB-705498 in a Validated Intranasal Capsaicin Challenge Model in Healthy Volunteers

description: This study is designed to look at the affect of SB-705498 on rhinitis symptoms, as induced by capsaicin challenge